RE:RE:RE:RE:Watch Dopesick on Disney PlusSome takeaways from webinar.....
Otena....transitioning to acute market, confidence that they won't see toxicity issue....eliminating duration issues, acute regiment of 5-6 days
targeting urgent need of rapid onset of pain relief in 60 minutes with better formulation
opportunity super strong pain killer
weekly phone calls from biotech wanting to merge
Never been in a lesser risk point, completely understand liver issues
Lots of runway for IP on all patents, longer the runway, bigger the reward
MrMugsy wrote: Exactly right Bagger ...
It takes a few listens to really get all the details.
One comment that Dan made that really got me thinking was ... lots of H2S learning over the past 3 years which adds to our understanding and intelectual property.
That comment may relate directly to the improved understanding of our drug, how it affect the liver - and - the move to amorphous OTENA ... but ... there's a lot more work being done in unrelated studies that just might show even greater superiority.
For example, studies like ... anit-inflammatory drugs may cause chronic pain in RA
and ...
studies like ... Opioids nearly double risk for venous thromboembolism vs. NSAIDs
also ...
investigations into ... Common anti-inflammatories my be ruining kids teeth
All seem to be playing into the hope that OTENA just might be better than other anti-inflammatory drugs.
If H2S is the body's manager of inflammation and if it provides cellular protection and cellular repair, to what extent does H2S reverse some of these other unwanted effects ?
Time will tell if we truly are better and exactly how much better.